Related Experiment Video
Updated: May 6, 2026
06:32
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 2, 2010
16.0K
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis
Vijay Ramaswamy1, Marc Remke, Eric Bouffet
1Division of Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada; Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
The Lancet. Oncology
|October 22, 2013
Summary
Recurrent medulloblastoma subgroup affiliation remains stable. SHH tumors recur locally, while group 3 and 4 tumors metastasize, informing targeted therapies.
Area of Science:
- Neuro-oncology
- Molecular oncology
- Pediatric oncology
Background:
- Recurrent medulloblastoma is a fatal condition with limited therapeutic options.
- Medulloblastoma comprises at least four distinct molecular subgroups.
- Understanding subgroup-specific recurrence patterns is crucial for improving outcomes.
Purpose of the Study:
- To investigate subgroup-specific differences in medulloblastoma recurrence patterns.
- To determine if molecular subgroup remains stable at recurrence.
- To correlate recurrence patterns with patient survival.
Main Methods:
- Retrospective analysis of three independent cohorts of recurrent medulloblastoma patients.
- Molecular subgrouping using nanoString-based assay on tumor tissues.
- Assessment of recurrence site (local vs. leptomeningeal metastasis), time to recurrence, and survival.
Main Results:
- Molecular subgroup remained stable in all matched primary and recurrent tumor pairs.
- SHH medulloblastomas showed a higher frequency of local recurrence (89%).
- Group 3 and Group 4 medulloblastomas were more commonly associated with metastatic recurrence (85%).
- Survival after recurrence was significantly longer for Group 4 tumors in two cohorts.
Conclusions:
- Medulloblastoma subgroups are stable at recurrence, validating the four main classifications.
- Subgroup-specific recurrence patterns (local vs. metastatic) have significant treatment implications.
- Intensified local therapy for SHH tumors and metastasis-focused therapy for Group 3/4 tumors are warranted.
